Free Trial

Syndax Pharmaceuticals (SNDX) Competitors

Syndax Pharmaceuticals logo
$8.82 -0.54 (-5.77%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$8.90 +0.08 (+0.91%)
As of 08:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNDX vs. AAPG, SRRK, MTSR, KYMR, VKTX, MOR, CRNX, ALVO, MLTX, and CPRX

Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), MoonLake Immunotherapeutics (MLTX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

Syndax Pharmaceuticals vs. Its Competitors

Syndax Pharmaceuticals (NASDAQ:SNDX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Ascentage Pharma Group International has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -757.53%. Ascentage Pharma Group International's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals-757.53% -101.60% -58.41%
Ascentage Pharma Group International N/A N/A N/A

Ascentage Pharma Group International has higher revenue and earnings than Syndax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$23.68M32.05-$318.76M-$3.86-2.28
Ascentage Pharma Group International$134.35M25.28-$55.54MN/AN/A

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Syndax Pharmaceuticals and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.11 beat Syndax Pharmaceuticals' score of 0.25 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Syndax Pharmaceuticals currently has a consensus target price of $35.80, indicating a potential upside of 305.90%. Given Syndax Pharmaceuticals' higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Ascentage Pharma Group International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ascentage Pharma Group International beats Syndax Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNDX vs. The Competition

MetricSyndax PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$805.83M$2.85B$5.48B$8.94B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio-2.2821.1726.2119.74
Price / Sales32.05262.85395.51109.12
Price / CashN/A41.8936.4957.06
Price / Book2.617.237.915.37
Net Income-$318.76M-$55.05M$3.15B$248.34M
7 Day Performance-0.90%-0.60%0.77%1.67%
1 Month Performance-19.67%3.77%3.46%4.56%
1 Year Performance-57.31%2.20%34.61%18.42%

Syndax Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNDX
Syndax Pharmaceuticals
3.0909 of 5 stars
$8.82
-5.8%
$35.80
+305.9%
-59.0%$805.83M$23.68M-2.28110Positive News
AAPG
Ascentage Pharma Group International
N/A$37.15
-0.6%
N/AN/A$3.26B$134.35M0.00600Positive News
SRRK
Scholar Rock
4.1162 of 5 stars
$33.28
-2.2%
$42.67
+28.2%
+315.3%$3.23B$33.19M-13.15140
MTSR
Metsera
N/A$29.00
-2.0%
$55.00
+89.7%
N/A$3.11BN/A0.0081Gap Down
KYMR
Kymera Therapeutics
3.0889 of 5 stars
$46.29
+0.9%
$59.82
+29.2%
+43.6%$2.99B$47.07M-14.93170Trending News
Insider Trade
Analyst Revision
VKTX
Viking Therapeutics
4.1532 of 5 stars
$24.86
-4.4%
$87.15
+250.6%
-51.8%$2.92BN/A-21.6220Positive News
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
CRNX
Crinetics Pharmaceuticals
3.5618 of 5 stars
$29.91
-0.8%
$74.56
+149.3%
-38.3%$2.82B$1.04M-7.83210
ALVO
Alvotech
3.7277 of 5 stars
$9.13
-2.4%
$18.00
+97.2%
-26.6%$2.82B$491.98M24.681,032
MLTX
MoonLake Immunotherapeutics
2.2733 of 5 stars
$44.87
+3.1%
$78.71
+75.4%
+11.5%$2.78BN/A-19.512
CPRX
Catalyst Pharmaceuticals
4.9337 of 5 stars
$22.12
-1.6%
$32.83
+48.4%
+34.4%$2.74B$491.73M14.0980Positive News

Related Companies and Tools


This page (NASDAQ:SNDX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners